Rodman & Renshaw analyst Tony Butler initiated coverage of Leap Therapeutics with a Buy rating and $8 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPTX:
- Leap Therapeutics price target lowered to $5.50 from $7 at H.C. Wainwright
- Leap Therapeutics reports Q1 EPS (51c), consensus (58c)
- Leap Therapeutics Reports First Quarter 2024 Financial Results
- LPTX Earnings this Week: How Will it Perform?
- Leap Therapeutics files to sell 14.18M shares of common stock for holders